RESUMEN
Cutaneous lichen planus (CLP) and psoriasis (PSO) are both common chronic inflammatory skin diseases for which development of new treatments requires the identification of key targets. While PSO is a typical Th17/IL-17-disorder, there is some evidence that Th1/IFN-É£ dominate the inflammatory process in CLP. Nonetheless, the immunopathogenesis of CLP is not fully explained and key immunological factors still have to be recognized. In this study, we compared the immune signature of CLP lesions with the well-characterized inflammation present in PSO skin. First, we analysed the histological and immunohistological characteristics of CLP and PSO. Second, we assessed the cytokine expression (IL1A, IL1B, IL4, IL6, IL8, IL10, IL17A, IL19, IL21, IL22, IL23A, IL13, IFNG, TNF, IL12A, IL12B and IL36G) of lesional skin of CLP with PSO by qPCR. Histology revealed a similar epidermal thickness in CLP and PSO. Immunohistochemically, both diseases presented with an inflammatory infiltrate mainly composed by CD3+ CD4+ T cells rather than CD3+ CD8+ . Importantly, mRNA analysis showed a distinct cytokine signature: while levels of IL12B, IL1A, IL6 and IL23 were similar between the two groups, the characteristic PSO-associated cytokines IL8, IL17A, IL22, IL19 and IL36G were expressed at very low levels in CLP. In contrast, CLP lesional skin was dominated by the expression of IFNG, IL21, IL4, IL12A and TNF. Immunohistochemistry confirmed the dominance of IL-21, IFN-É£ and also pSTAT1 in the dermal infiltrate of CLP, while IL-17A was more present in PSO. Collectively, this study improves our understanding of the immunological factors dominating CLP. The dominating cytokines and signalling proteins identified suggest that anti-cytokine therapeutics like JAK inhibitors may be beneficial in CLP.
Asunto(s)
Citocinas/genética , Liquen Plano/genética , Liquen Plano/inmunología , Psoriasis/genética , Psoriasis/inmunología , Adolescente , Adulto , Anciano , Linfocitos T CD4-Positivos/patología , Niño , Citocinas/metabolismo , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Interferón gamma/genética , Interferón gamma/metabolismo , Interleucina-17/metabolismo , Interleucina-8/genética , Interleucinas/genética , Interleucinas/metabolismo , Janus Quinasa 1/antagonistas & inhibidores , Liquen Plano/tratamiento farmacológico , Liquen Plano/patología , Masculino , Persona de Mediana Edad , Psoriasis/patología , ARN Mensajero/metabolismo , Factor de Transcripción STAT1/metabolismo , Adulto JovenAsunto(s)
Urticaria Crónica/inducido químicamente , Erupciones por Medicamentos/etiología , Hipoglucemiantes/efectos adversos , Insulinas/efectos adversos , Anciano , Antialérgicos/uso terapéutico , Cetirizina/uso terapéutico , Urticaria Crónica/diagnóstico , Urticaria Crónica/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/tratamiento farmacológico , Sustitución de Medicamentos , Humanos , Inmunoglobulina E/fisiología , MasculinoRESUMEN
BACKGROUND: The treatment of persistent erythema and flushing episodes in patients with rosacea remains a clinical challenge. A possible therapeutic option could be the use of antihypertensive drugs. OBJECTIVES: We therefore evaluated the effect of the non-selective ß-blocker carvedilol in five Caucasian patients. METHODS: In a monocentric retrospective case study, the patients were treated with carvedilol titrated up to 12.5 mg twice a day over at least six months. Patients self assessment (PSA), clinicians erythema assessment (CEA), and the patients levels of embarrassment and satisfaction were performed by questionaires. RESULTS: The CEA grade description as well as the PSA grade description decreased remarkably in all five patients. Furthermore, all patients reported to have a major improvement of their level of satisfaction and no feelings of embarrassment anymore. CONCLUSIONS: These findings demonstrate that facial flushing and persistent erythema can be effectively treated by carvedilol long-term with a fast onset of improvement in a dose well tolerated.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Carbazoles/uso terapéutico , Eritema/tratamiento farmacológico , Rubor/tratamiento farmacológico , Propanolaminas/uso terapéutico , Rosácea/patología , Adulto , Carvedilol , Eritema/etiología , Femenino , Humanos , Persona de Mediana Edad , Satisfacción del Paciente , Estudios Retrospectivos , Rosácea/complicaciones , Encuestas y CuestionariosRESUMEN
BACKGROUND: Prostate cancer is one of the leading malignant tumors in men. Current therapies are associated with severe side effects making it problematic for many multi-morbid patients to receive treatment. Prostate specific antigen, serum response factor (SRF), signal transducer and activator of transcription-3 (STAT3), hypoxia-inducible factor-1α (HIF-1α), HIF-2α, E2F1 and Survivin are well known proteins being overexpressed in cancer cells, expediting cell growth and also demonstrated in prostate cancer cells. Targeting these genes using the RNA-Interference pathway could be a new approach for prostate cancer therapy with fewer side effects. METHODS: Three prostate cancer cell lines were cultured under standard conditions and transfected with three different concentrations (25 nM, 50 nM, 100 nM) of specific small interfering RNAs (siRNAs) targeting SRF, STAT3, HIF1α, HIF2α, E2F1 and Survivin in a non-viral manner. Cells treated with non-specific siRNA (SCR-siRNA) served as control. Changes of messenger RNA (mRNA) levels were determined using quantitative real-time polymerase chain reaction (qRT-PCR). The analysis of the effect of siRNA on the number of cells was detected using CASY cell counter system. RESULTS: Transfections of the PC-3 cell line with specific siRNA especially against Survivin, E2F1, HIF1α- and HIF2α-siRNA resulted in a significant reduction of intracellular mRNA concentration together with a significant decreased number of cells. In the LnCAP and DU-145 cell lines Survivin and E2F1 showed similar effects. The impact of silencing STAT3 or SRF showed little influence on the amount of cells in all three cell lines. CONCLUSIONS: This study shows that RNAi succeeds in silencing gene expression and reducing the number of cells in differing dimensions depending on the transfected cell line and used siRNA.